174 related articles for article (PubMed ID: 23011175)
21. [Comparative study on the efficacy and safety of continuous versus twice-daily 3-hour infusion of cyclosporine A in pediatric hematopoietic stem cell transplantation].
Nodomi S; Umeda K; Matsubara H; Daifu T; Kato I; Hiramatsu H; Watanabe K; Heike T; Adachi S
Rinsho Ketsueki; 2012 Nov; 53(11):1891-7. PubMed ID: 23257669
[TBL] [Abstract][Full Text] [Related]
22. [Relative bioavailability of cyclosporine A-loaded hydroxypropyl methylcellulose phthalate nanoparticles for oral administration in rats].
Wang XQ; Dai JD; Zhang Q; Zhang T; Xia GM
Yao Xue Xue Bao; 2004 Jun; 39(6):463-6. PubMed ID: 15491107
[TBL] [Abstract][Full Text] [Related]
23. Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation.
Nygaard M; Hovgaard D; Schjødt IM; Andersen NS; Vindeløv L; Sengeløv H
J Clin Pharm Ther; 2015 Jun; 40(3):358-61. PubMed ID: 25829023
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation.
Furukawa T; Kurasaki-Ida T; Masuko M; Tsukada N; Okazuka K; Sato N; Yano T; Abe T; Momoi A; Shibasaki Y; Higashimura M; Karimata K; Moriyama M; Kuroha T; Takizawa J; Toba K; Narita M; Fuse I; Takahashi M; Aizawa Y
Int J Hematol; 2010 Jul; 92(1):144-51. PubMed ID: 20533008
[TBL] [Abstract][Full Text] [Related]
25. Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation.
Jacobson PA; Ng J; Green KG; Rogosheske J; Brundage R
Biol Blood Marrow Transplant; 2003 May; 9(5):304-11. PubMed ID: 12766880
[TBL] [Abstract][Full Text] [Related]
26. Optimal initial dose of orally administered cyclosporine following intravenous cyclosporine therapy.
Ishizawa T; Sugawara Y; Ikeda M; Hasegawa K; Makuuchi M
Transplant Proc; 2005 Dec; 37(10):4370-2. PubMed ID: 16387123
[TBL] [Abstract][Full Text] [Related]
27. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
[TBL] [Abstract][Full Text] [Related]
28. Risk factors of cyclosporine nephrotoxicity after conversion from Sandimmune to Neoral.
Sijpkens YW; Mallat MJ; Siegert CE; Zwinderman AH; Westendorp RG; de Fijter JW; van Es LA; Paul LC
Clin Nephrol; 2001 Feb; 55(2):149-55. PubMed ID: 11269679
[TBL] [Abstract][Full Text] [Related]
29. Limited sampling strategies for estimating intravenous and oral cyclosporine area under the curve in pediatric hematopoietic stem cell transplantation.
Sarem S; Nekka F; Barrière O; Bittencourt H; Duval M; Teira P; Haddad E; Théorêt Y; Lapeyraque AL; Litalien C
Ther Drug Monit; 2015 Apr; 37(2):198-205. PubMed ID: 25162214
[TBL] [Abstract][Full Text] [Related]
30. Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals.
Atiq F; Hameli E; Broers AEC; Doorduijn JK; Van Gelder T; Andrews LM; Koch BCP; Versmissen J; de Winter BCM
Eur J Clin Pharmacol; 2018 Jun; 74(6):767-773. PubMed ID: 29500599
[TBL] [Abstract][Full Text] [Related]
31. Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: twice daily vs. once daily dosing.
Fukudo M; Yano I; Masuda S; Katsura T; Ogura Y; Oike F; Takada Y; Tanaka K; Inui K
Liver Transpl; 2006 Feb; 12(2):292-300. PubMed ID: 16447186
[TBL] [Abstract][Full Text] [Related]
32. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group.
Hoyer PF
Pediatr Transplant; 1998 Feb; 2(1):35-9. PubMed ID: 10084758
[TBL] [Abstract][Full Text] [Related]
33. Disposition of two oral formulations of cyclosporine in pediatric patients receiving hematopoietic stem cell transplants.
Dupuis LL; Taylor T; Saunders EF
Pharmacotherapy; 2006 Jan; 26(1):15-22. PubMed ID: 16509024
[TBL] [Abstract][Full Text] [Related]
34. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral.
Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R
Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433
[TBL] [Abstract][Full Text] [Related]
35. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
Kumar S; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Harmsen WS; Litzow MR
Bone Marrow Transplant; 2001 Jun; 27(11):1133-40. PubMed ID: 11551023
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics for once-daily modified release formulation of tacrolimus hydrate in unrelated hematopoietic stem cell transplantation.
Yano S; Mori S; Saito T; Yokoyama H; Machishima T; Shimada T; Yahagi Y; Sugiyama K; Ogasawara Y; Takahara S; Kasama K; Katsube A; Kamiyama Y; Suzuki K; Inui Y; Usui N; Aiba K; Yamashita T
Ann Hematol; 2015 Mar; 94(3):491-6. PubMed ID: 25325985
[TBL] [Abstract][Full Text] [Related]
37. [Preparation of cyclosporine A pH sensitive nanoparticles and oral pharmacokinetics in rats].
Dai JD; Wang XQ; Zhang T; Meng M; Zhang X; Lü WL; Zhang Q
Yao Xue Xue Bao; 2004 Dec; 39(12):1023-7. PubMed ID: 15813034
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of limited sampling strategies for estimation of cyclosporine area under the concentration-time curve in hematopoietic stem cell transplant patients.
Hadjibabaie M; Vazirian I; Iravani M; Moosavi SA; Alimoghaddam K; Ghavamzadeh A; Rezaee S
Ther Drug Monit; 2011 Dec; 33(6):673-80. PubMed ID: 22011723
[TBL] [Abstract][Full Text] [Related]
39. Severe Anaphylaxis During Allogeneic Hematopoietic Stem Cell Transplantation in a Patient with Aplastic Anemia: Case Report of Individualized Pharmaceutical Care and Literature Review.
Peng H; Ji D; Ren S; Zou D; Li F; Huang R
Clin Lab; 2020 Mar; 66(3):. PubMed ID: 32162881
[TBL] [Abstract][Full Text] [Related]
40. Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation.
Jacobson P; Green K; Rogosheske J; Brunstein C; Ebeling B; DeFor T; McGlave P; Weisdorf D
J Clin Pharmacol; 2007 Jan; 47(1):6-12. PubMed ID: 17192496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
